



## **Nexstim Receives NBS 5 System Order from New Customer in Ohio, United States**

*Press release, Helsinki, 9 January 2025 at 10 AM (EET)*

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 with NexSpeech module from a healthcare provider in Ohio, United States.

This new customer is planning to use their NBS 5 device for the preprocedural mapping of motor and speech areas. The nTMS data can then be used to evaluate risks, plan invasive procedures, and it can be integrated with surgical planning software to assist with invasive neuromonitoring in the operating room. This system also includes therapeutic capabilities that allow the system to be used for the treatment of major depressive disorder (MDD).

The Nexstim NBS System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The system provides information that may be used in the assessment of the primary motor cortex for pre-procedural planning.

Nexstim NexSpeech®, when used together with the NBS System 5, is indicated for non-invasive localization of cortical areas that do not contain essential speech function. NexSpeech® provides information that may be used in pre-surgical planning in patients undergoing brain surgery. Intra-operatively, the localization information provided by NexSpeech® is intended to be verified by direct cortical stimulation. The Nexstim NBS System 5 and NBS System 5 with NexSpeech® are not intended to be used during a surgical procedure. The Nexstim NBS System 5 and NBS System 5 with NexSpeech® are intended to be used by trained clinical professionals.

Nexstim's systems are based on the company's unique navigated transcranial magnetic stimulation (nTMS) technology.

Mikko Karvinen, CEO of Nexstim, comments: *"We are excited to welcome this new customer to our growing nTMS user community in the United States and making Nexstim technology accessible to their patients in Ohio."*

**Further information is available on the website [www.nexstim.com](http://www.nexstim.com), or by contacting:**

**Mikko Karvinen, CEO**

+358 50 326 4101

[mikko.karvinen@nexstim.com](mailto:mikko.karvinen@nexstim.com)

### **About Nexstim Plc**

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit [www.nexstim.com](http://www.nexstim.com)